Table 2.
Outcomes assessment
|
|
Initial urologic assessment (10-14 wk)
|
|
Follow up urologic assessment (21-28 mo)
|
|
| OAB symptom score median (range) | QoL score median (range) | OAB symptom score median (range) | Qol score median (range) | |
| New symptoms (n = 250)a | 18 (12-21) | 19 (16-24) | 9 (4-21) | 9 (7-20) |
| Worsening symptoms (n = 100)b | 19 (17-21)c | 20 (19-20)c | 13 (5-21) | 14 (6-20) |
| Female (n = 140) | 18 (15-21) | 19 (16-21) | 8 (4-21) | 7 (6-22) |
| Male (n = 210) | 18 (12-20) | 19 (16-20) | 7 (5-20) | 8 (6-23) |
a
30 patients lost to follow up.
b
10 patients lost to follow up.
c
Pre-COVID OAB and QoL median score: 8 (range 4-10) and 9 (8-10) respectively.
CAC: COVID-associated cystitis; OAB: Overactive bladder; QoL: Quality of life.